Naperville, IL -- (SBWIRE) -- 12/30/2014 -- Reportstack, provider of premium market research reports announces the addition of Cardiovascular Pharmaceuticals Market in India 2014 market report to its offering
Netscribes latest market research report titled Cardiovascular Pharmaceutical Market in India 2014 highlights the analysis of the drivers and explains the factors for growth of the industry. Increasing patient population, patent expiry of blockbuster drugs, and introduction of newer and better drugs are the key drivers of this market. Cardiovascular pharmaceuticals is one of the leading therapeutic segments of the overall pharma industry and cardiovascular diseases (CVDs) are the top causes of deaths worldwide
Growing incidences of cardiovascular diseases is helping the Indian market to grow and large pharmaceutical companies are trying to launch new patented blockbuster drugs to tackle the situation. Patented blockbuster drugs, after becoming generic, present a huge opportunity for growth. Generic drugs increase the affordability among patients, which helps in the growth of the market. The increasing disposable income of people are also helping to boost the market size. Some challenges faced by the industry are the internal competition between large pharmaceutical companies and competition from complementary and alternative medicines. Various government initiatives have been undertaken to reduce the drug prices and various tax reforms and control programs are promoting the growth of the market as well
1. AstraZeneca Pharma India Ltd.
2. Sanofi India Ltd.
3. Cipla Ltd.
4. Dr. Reddys Laboratories Ltd.
5. GlaxoSmithKline Pharmaceuticals Ltd.
6. Lupin Ltd.
7. Merck Ltd.
8. Novartis India Ltd.
9. Pfizer Ltd.
10. Ranbaxy Laboratories Ltd.
11. Sun Pharmaceutical Industries Ltd.
12. Torrent Pharmaceutical Ltd.
1. Bristol-Myers Squibb India Pvt. Ltd.
2. Cadila Pharmaceuticals Ltd.
3. Intas Pharmaceuticals Ltd.
4. USV Ltd.
Complete report is available